Fundraising FoxOno Venture Investment, Inc. — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Co-investorsARCH Venture PartnersGreatPoint VenturesIllumina VenturesTCG CrossoverAlly Bridge GroupJanus Henderson Investors+5 more
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(CEO)inDan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsAgent CapitalDC Investment PartnersLifelinkLongwood FundM VenturesMedical Excellence Capital+5 more
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtechStanford, US
Thorsten Stafforst(Chairman of the Board of Directors)inKris ElveruminTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in
BoardRodger Novak(Chair)in
Co-investors+ND CapitalARCH Venture PartnersForbionVenrockFast Track InitiativeLifelink+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.